CDC study shows risk of Guillain-Barré syndrome elevated after Ad.26.COV2.S COVID vaccination

To date, three vaccines have been granted emergency used authorization (EUA) in the United States (US) to prevent coronavirus disease 2019 (COVID-19). These vaccines include BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), both of which are mRNA-based vaccines, as well as Ad.26.COV2.S (Janssen).

BNT162b2 and mRNA-1273 are both administered primarily as double-doses, with a third booster shot that has recently been approved after six months. The Ad.26.COV2.S is a replication-incompetent adenoviral vector vaccine and is primarily administered as a single dose; however, the U.S. Food and Drug Administration (FDA) has recently advised Ad.26.COV2.S recipients to receive a booster dose of any approved COVID-19 vaccine after two months.

...

Guillain-Barré syndrome (GBS) is a rare neurological disorder with an incidence rate of 1-2 per 100,000 person-years. In July 2021, data from the Vaccine Adverse Event Reporting System (VAERS) indicated that more cases of GBS were being reported after vaccination with Ad.26.COV2.S in comparison to other mRNA vaccines.

...

This interim analysis of surveillance data of COVID-19 vaccines demonstrates that there is an elevated risk of GBS observed after primary Ad.26.COV2.S vaccination. Surveillance is ongoing and more results are awaited.

----- SNIP -----

Source: [link to www.news-medical.net (secure)]

Is this the beginning of the avalanche? Or has it already taken place and it's just not being reported as such, as seen with other disorders such as increases in hypertension and blood-clots?